It has been established that obesity itself alters HDL metabolism (particularly apoA-1) [44], and it may be that the presence of anti-apoA-1 antibodies augments this derangement and therefore enhances CVD risk. Here, APOA1 is linked to obesity due to melanocortin 4 receptor deficiency.